Cagrilintide
Cagrilintide (AM833, NNC0174-0833)
Long-acting synthetic amylin analogue for weight management and type 2 diabetes. Works as a dual amylin and calcitonin receptor agonist (DACRA), mimicking natural amylin hormone to regulate appetite, slow gastric emptying, and promote satiety.
Complete Dosing Guide
Possible Side Effects
Common Side Effects (Dose-Dependent):
- Nausea (20-47% with monotherapy, higher with CagriSema)
- Constipation (common due to slowed gastric emptying)
- Vomiting (less common than with GLP-1 agonists alone)
- Diarrhea
- Abdominal pain
- Injection site reactions
Less Common Side Effects:
- Decreased appetite
- Dyspepsia
- Fatigue
- Dizziness
- Headache
Rare but Serious Side Effects:
- Acute cholelithiasis (gallstones)
- Pancreatitis (theoretical risk)
- Severe hypoglycemia (when combined with insulin or sulfonylureas)
Note: Most GI side effects are transient, mild-to-moderate, and improve with continued use.
Possible Side Effects
Common Side Effects (Dose-Dependent):
- Nausea (20-47% with monotherapy, higher with CagriSema)
- Constipation (common due to slowed gastric emptying)
- Vomiting (less common than with GLP-1 agonists alone)
- Diarrhea
- Abdominal pain
- Injection site reactions
Less Common Side Effects:
- Decreased appetite
- Dyspepsia
- Fatigue
- Dizziness
- Headache
Rare but Serious Side Effects:
- Acute cholelithiasis (gallstones)
- Pancreatitis (theoretical risk)
- Severe hypoglycemia (when combined with insulin or sulfonylureas)
Note: Most GI side effects are transient, mild-to-moderate, and improve with continued use.
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.